Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy

NCT03993912 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

294

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Daratumumab SC in combination with Lenalidomide
DRUG: Lenalidomide PO (25mg)
DRUG: Dexamethasone PO (20mg): days 1, 8, 15, 22 of each 28-day cycle, until progression

Sponsor

University Hospital, Lille